| ID | 1165 |
| Name of the vaccine | EasyFive-TT |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | From 6 weeks |
| Description of the vaccine | Pentavalent vaccine (DTwP-HepB-Hib). |
| Name of the manufacturer | Panacea Biotech Ltd. |
| Name of the manufacturing country | India |
| Year of manufacture | 2009 |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | The anti-PRP seroprotection rate was 89.5%. |
| Vaccine formulation | Sterile and uniform suspension in multidose vial. |
| Dosage | First dose as early as 6 weeks and two subsequent doses given at 4 week interval. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria, tetanus, whole cell pertussis, hepatitis B and Haemophilus influenzae type b infections. |
| Export | Marketing Authorisation Holder: Panacea Biotech Ltd, India |
| Approval | WHO |
| Adjuvant | Aluminium phosphate |
| Repurposing | For diphtheria, tetanus, whole cell pertussis, hepatitis B. |
| Side effects of vaccine | Temporary swelling, tenderness and redness together with fever, feeding disorders, sleepiness, irritability |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.who.int/immunization_standards/vaccine_quality/pq_270_penta_panacea_10dose_product_insert.pdf?ua=1 |
| Other name | NA |
| Additional Links | https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadSmPC/1850ml.pdf
|